TY - JOUR
T1 - Standardized Mori ramulus extract improves insulin secretion and insulin sensitivity in C57BLKS/J db/db mice and INS-1 cells
AU - Park, Soo yeon
AU - Jin, Bora
AU - Shin, Jae Ho
AU - Adisakwattana, Sirichai
AU - Kwon, Oran
N1 - Publisher Copyright:
© 2017 Elsevier Masson SAS
PY - 2017/8
Y1 - 2017/8
N2 - Abnormalities in the hyperbolic relationship between insulin sensitivity and insulin secretion may cause oxidative stress and non-enzymatic glycation, resulting in an increased risk of type 2 diabetes. Here, we performed a 14-week study to investigate the effects of ethanolic extract of Mori ramulus (MRE; 0, 800, and 1600 mg/kg body weight) and its signature component oxyresveratrol (OXY; 800 mg/kg body weight) on β-cell dysfunction and insulin resistance in C57BLKS/J db/db mice fed with a high-fat diet. Compared with the diabetic control group, the high-dose MRE group showed a significant decrease in fasting blood glucose (p = 0.0024); a significant increase in insulin secretion as measured by insulin (p = 0.0012) and C-peptide (p = 0.0103) levels in plasma and insulin content (p = 0.0440) and homeobox factor-1 protein expression (p = 0.0148) in the pancreas; and a significant increase in insulin sensitivity as measured by insulin receptor mRNA expression in the liver (p = 0.0179) and adipose tissue (p = 0.0491). In addition, improvements in the reactive oxygen species level and inflammatory pancreatic and hepatic tissue damage were also observed in the MRE group as assessed by histological findings. A similar but weaker effect was found in the OXY group. Furthermore, we observed a potentiating effect of MRE and OXY on insulin secretion in INS-1 cells in the presence of 27 mM glucose, together with an anti-glycation effect as indicated by methylglyoxal-trapping capacity and inhibition of advanced glycation end-product formation. Taken together, these data suggest that MRE could ameliorate β-cell dysfunction and insulin resistance by reducing oxidative damage and advanced glycation end-product (Wagenknecht et al., 2003) formation and that these effects are due, at least in part, to OXY.
AB - Abnormalities in the hyperbolic relationship between insulin sensitivity and insulin secretion may cause oxidative stress and non-enzymatic glycation, resulting in an increased risk of type 2 diabetes. Here, we performed a 14-week study to investigate the effects of ethanolic extract of Mori ramulus (MRE; 0, 800, and 1600 mg/kg body weight) and its signature component oxyresveratrol (OXY; 800 mg/kg body weight) on β-cell dysfunction and insulin resistance in C57BLKS/J db/db mice fed with a high-fat diet. Compared with the diabetic control group, the high-dose MRE group showed a significant decrease in fasting blood glucose (p = 0.0024); a significant increase in insulin secretion as measured by insulin (p = 0.0012) and C-peptide (p = 0.0103) levels in plasma and insulin content (p = 0.0440) and homeobox factor-1 protein expression (p = 0.0148) in the pancreas; and a significant increase in insulin sensitivity as measured by insulin receptor mRNA expression in the liver (p = 0.0179) and adipose tissue (p = 0.0491). In addition, improvements in the reactive oxygen species level and inflammatory pancreatic and hepatic tissue damage were also observed in the MRE group as assessed by histological findings. A similar but weaker effect was found in the OXY group. Furthermore, we observed a potentiating effect of MRE and OXY on insulin secretion in INS-1 cells in the presence of 27 mM glucose, together with an anti-glycation effect as indicated by methylglyoxal-trapping capacity and inhibition of advanced glycation end-product formation. Taken together, these data suggest that MRE could ameliorate β-cell dysfunction and insulin resistance by reducing oxidative damage and advanced glycation end-product (Wagenknecht et al., 2003) formation and that these effects are due, at least in part, to OXY.
KW - Advanced glycation end-products
KW - Hyperglycemia
KW - Insulin resistance
KW - Mori ramulus
KW - Oxyresveratrol
KW - Pancreatic β-cell dysfunction
UR - http://www.scopus.com/inward/record.url?scp=85019882967&partnerID=8YFLogxK
U2 - 10.1016/j.biopha.2017.05.080
DO - 10.1016/j.biopha.2017.05.080
M3 - Article
C2 - 28551552
AN - SCOPUS:85019882967
SN - 0753-3322
VL - 92
SP - 308
EP - 315
JO - Biomedicine and Pharmacotherapy
JF - Biomedicine and Pharmacotherapy
ER -